(Clomipramine hydrochloride + sildenafil citrate) is under clinical development by Ctcbio and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect (Clomipramine hydrochloride + sildenafil citrate)’s likelihood of approval (LoA) and phase transition for Premature Ejaculation took place on 07 Jun 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Clomipramine hydrochloride + sildenafil citrate) Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

(Clomipramine hydrochloride + sildenafil citrate) overview

Clomipramine hydrochloride in combination with sildenafil citrate (CDFR-0812) is under development for the treatment of premature ejaculation. It is administered as tablet through oral route. Clomipramine hydrochloride acts by targeting serotonin and PDE5 receptor and sildenafil citrate targets phosphodiesterase type 5 (PDE5).

Ctcbio overview

Ctcbio is a biotechnology company that manufactures and markets pharmaceuticals, veterinary drugs, animal feed supplements, and functional food products. The company’s business segments include pharmaceutical, animal health, and functional food. Its functional food business includes the development and manufacture of enzymes, lactobacillus, and related products used in dairy products. Ctcbio’s animal health division provides various products made from materials on the basis of medical treatment, ferment, functional improvement, and bionics technology. The company offers technology platforms such as gene and protein manipulation, assay technology, microorganism development and screening, fermentation and purification, and process optimization. Ctcbio is headquartered in Songpa-gu, Seoul, South Korea.

Quick View (Clomipramine hydrochloride + sildenafil citrate) LOA Data

Report Segments
  • Innovator
Drug Name
  • (Clomipramine hydrochloride + sildenafil citrate)
Administration Pathway
  • Oral
Therapeutic Areas
  • Male Health
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.